

# 2025 Brachytherapy Publication

---

*Radiation Therapy*

RT-BRAC-MOH  
Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 07/31/2025  
**Previous Review Date:** 05/23/2025  
**Guideline Initiated:** 06/30/2019






A WNS COMPANY

# Table of Contents

- 2025 Brachytherapy Blood, Bone and Lymphatic Cancers ..... 6
  - Brachytherapy for Blood, Bone Marrow and Lymphatic System Cancer ..... 6
    - Acute Lymphoblastic Leukemia • Acute Myeloid Leukemia • Bone Cancer •
    - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Chronic
    - Myeloid Leukemia • Hairy Cell Leukemia • Histiocytic Neoplasms • Systemic
    - Light Chain Amyloidosis Guideline ..... 6
    - B-Cell Lymphomas • Hodgkin Lymphoma • Multiple Myeloma • Primary
    - Cutaneous Lymphomas • T-Cell Lymphomas • Waldenstrom Macroglobulinemia/
    - Lymphoplasmacytic Lymphoma Guideline ..... 6
    - Myelodysplastic Syndromes • Myeloid/Lymphoid Neoplasms with Eosinophilia
    - and Tyrosine Kinase Gene Fusions • Myeloproliferative Neoplasms • Systemic
    - Mastocytosis Guideline ..... 7
    - Brachytherapy Procedure Codes ..... 7
    - Brachytherapy Blood, Bone Marrow and Lymphatic System Cancer Summary of
    - Changes ..... 8
    - Brachytherapy Blood, Bone Marrow and Lymphatic System Cancer References ..... 8
- 2025 Brachytherapy Breast Cancer ..... 10
  - Brachytherapy for Breast Cancer ..... 10
    - Ductal Carcinoma in Situ (DCIS) and Invasive Breast Cancer Guideline ..... 10
    - Brachytherapy Procedure Codes ..... 11
    - Brachytherapy Breast Cancer Summary of Changes ..... 12
  - Brachytherapy Breast Cancer References ..... 12
- 2025 Brachytherapy Central Nervous System Cancer ..... 13
  - Brachytherapy for Central Nervous System Cancer ..... 13
    - Glioma • Intracranial and Spinal Ependymoma • Medulloblastoma • Extensive
    - Brain Metastases • Glioblastoma • Leptomeningeal Metastases • Limited Brain
    - Metastases • Meningiomas • Metastatic Spine Tumors • Primary Central
    - Nervous System Lymphoma • Primary Spinal Cord Tumors Guideline ..... 13
    - Brachytherapy Procedure Codes ..... 14
    - Brachytherapy Central Nervous System Summary of Changes ..... 14
  - Brachytherapy Central Nervous System Cancer References ..... 14
- 2025 Brachytherapy Gastrointestinal Cancer ..... 15
  - Brachytherapy for Gastrointestinal Cancer ..... 15
    - Appendiceal Adenocarcinoma • Colon Cancer • Gastric Cancer • Rectal Cancer
    - Guideline ..... 15
    - Anal Cancer Guideline ..... 15





A WNS COMPANY

Esophageal Cancer Guideline .....	16
Brachytherapy Procedure Codes .....	16
Brachytherapy Gastrointestinal Cancer Summary of Changes .....	17
Brachytherapy Gastrointestinal Cancer References .....	17
2025 Brachytherapy Genitourinary Cancer .....	18
Brachytherapy for Genitourinary Cancer .....	19
Bladder Cancer • Kidney Cancer • Post-Prostatectomy • Prostate Cancer, Very Low to Low Risk • Testicular Cancer Guideline .....	19
Prostate Cancer, Favorable Intermediate Risk .....	19
Penile Cancer Guideline .....	19
Prostate Cancer, High and Very High Risk (Gleason Score of 8 to 10 <b>OR</b> PSA greater than 20) Guideline .....	20
Prostate Cancer, Unfavorable Intermediate Risk (Gleason Score of 7 <b>OR</b> PSA 10-20) Guideline .....	20
Brachytherapy Procedure Codes .....	21
Brachytherapy Genitourinary Cancer Summary of Changes .....	22
Brachytherapy Genitourinary Cancer References .....	22
2025 Brachytherapy Gynecological Cancer .....	23
Brachytherapy for Gynecological Cancer .....	23
Cervical Cancer Guideline .....	23
Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Guideline ...	24
Uterine Neoplasms Guideline .....	24
Vaginal Cancer Guideline .....	25
Vulvovaginal Melanoma Guideline .....	25
Brachytherapy Procedure Codes .....	26
Brachytherapy Gynecological Cancer Summary of Changes .....	27
Brachytherapy Gynecological Cancer References .....	27
2025 Brachytherapy Head and Neck Cancer .....	28
Brachytherapy for Head and Neck Cancer .....	28
Ethmoid Sinus Tumors • Maxillary Sinus Tumors • Mucosal Melanoma • Oral Cavity Cancer Guideline .....	28
Hypopharynx Cancer • Laryngeal Cancer • Nasopharynx Cancer • Oropharynx Cancer Guideline .....	28
Thyroid Carcinoma Guideline .....	29
Uveal Melanoma Guideline .....	29
Brachytherapy Procedure Codes .....	30
Brachytherapy Head and Neck Cancer Summary of Changes .....	30
Brachytherapy Head and Neck Cancer References .....	30



A WNS COMPANY

2025 Brachytherapy Hepatobiliary Cancer .....	31
Brachytherapy for Hepatobiliary Cancer .....	32
Ampullary Adenocarcinoma Guideline .....	32
Biliary Tract (Gallbladder • Intrahepatic Cholangiocarcinoma • Extrahepatic Cholangiocarcinoma) Cancer Guideline .....	32
Hepatocellular Carcinoma Guideline .....	32
Pancreatic Adenocarcinoma Guideline .....	32
Brachytherapy Procedure Codes .....	33
Brachytherapy Hepatobiliary Cancer Summary of Changes .....	34
Brachytherapy Hepatobiliary Cancer References .....	34
2025 Brachytherapy Pediatric Cancers .....	35
Brachytherapy for Pediatric Cancers .....	35
Pediatric Cancers Guideline .....	35
Brachytherapy Procedure Codes .....	35
Brachytherapy Pediatric Cancers Summary of Changes .....	36
Brachytherapy for Pediatric Cancer References .....	36
2025 Brachytherapy Sarcoma .....	37
Brachytherapy for Sarcoma .....	37
Desmoid Tumors Guideline .....	37
Kaposi Sarcoma Guideline .....	37
Retroperitoneal/Intra-Abdominal Sarcoma Guideline .....	37
Soft Tissue Sarcoma of Extremity, Body Wall or Head and Neck Guideline .....	38
Brachytherapy Procedure Codes .....	39
Brachytherapy Sarcoma Summary of Changes .....	39
Brachytherapy Sarcoma References .....	40
2025 Brachytherapy Skin Cancer .....	40
Brachytherapy for Skin Cancer .....	40
Basal Cell Skin Cancer Guideline .....	40
Dermatofibrosarcoma Protuberans, Melanoma and Merkel Cell Carcinoma Guideline .....	41
Squamous Cell Skin Cancer Guideline .....	41
Brachytherapy Procedure Codes .....	41
Brachytherapy Skin Cancer Summary of Changes .....	42
Brachytherapy Skin Cancer References .....	43
2025 Brachytherapy Thoracic Cancer .....	43
Brachytherapy for Thoracic Cancer .....	44
Mesothelioma, Non-Small Cell Lung Cancer Stage I-III, Small Cell Lung Cancer Limited and Extensive Stage and Thymoma/Thymic Cancer Guideline .....	44



A WNS COMPANY

Brachytherapy Procedure Codes .....	44
Brachytherapy Thoracic Cancer Summary of Changes .....	45
Brachytherapy Thoracic Cancer References .....	45
Brachytherapy definition section .....	45
Disclaimer section .....	53
Purpose .....	53
Clinician Review .....	54
Payment .....	54
Registered Trademarks (®/™) and Copyright (©) .....	54
National and Local Coverage Determination (NCD and LCD) .....	54
Background .....	54
Medical Necessity Codes .....	55



## 2025 Brachytherapy Blood, Bone and Lymphatic Cancers

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Blood, Bone Marrow and Lymphatic System Cancer

### Acute Lymphoblastic Leukemia • Acute Myeloid Leukemia • Bone Cancer • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Chronic Myeloid Leukemia • Hairy Cell Leukemia • Histiocytic Neoplasms • Systemic Light Chain Amyloidosis Guideline

Brachytherapy for acute lymphoblastic leukemia, acute myeloid leukemia, bone cancer, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, hairy cell leukemia, systemic light chain amyloidosis and histiocytic neoplasms: [1] [5] [13] [14] [15] [16] [17] [11]

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

### B-Cell Lymphomas • Hodgkin Lymphoma • Multiple Myeloma • Primary Cutaneous Lymphomas • T-Cell Lymphomas • Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Guideline

Brachytherapy for b-cell lymphomas, hodgkin lymphoma, multiple myeloma, primary cutaneous lymphomas, t-cell lymphomas and waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: [7] [10] [9] [12] [18] [8]

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

## Myelodysplastic Syndromes • Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions • Myeloproliferative Neoplasms • Systemic Mastocytosis Guideline

Brachytherapy for myelodysplastic syndromes, myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, systemic mastocytosis and myeloproliferative neoplasms: [3] [6] [4] [2]

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.



### LCD 37779

See also, **LCD 37779**: Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels

CODE	DESCRIPTION
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Blood, Bone Marrow and Lymphatic System Cancer Summary of Changes

Brachytherapy blood, bone marrow and lymphatic system cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Citations updated, evidence review completed.

## Brachytherapy Blood, Bone Marrow and Lymphatic System Cancer References

- [1] Bierman, J.S., Hirbe, A., . . . Yoon, J. (2025). Bone Cancer Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf)
- [2] Gerds, A.T., Gotlib, J., . . . Wall, S. (2025). Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 1.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/mlne.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mlne.pdf)
- [3] Gerds, A.T., Gotlib, J., . . . Wall, S. A.(2025). Myeloproliferative Neoplasms Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/mpn.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf)
- [4] Gerds, A.T., Gotlib, J., . . . Wall, S. A. (2025). Systemic Mastocytosis Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/mastocytosis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf)
- [5] Go, R.S., Jacobsen, E., . . . Zurbriggen, L. (2025). Histiocytic Neoplasms Version 3.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/histiocytic\\_neoplasms.pdf](https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf)
- [6] Greenberg, P.L., Stone, R.M., . . . Thota, S. (2025). Myelodysplastic Syndromes Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/mds.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf)

- [7] Hoppe, R.T., Advani, R.H., . . . Yang, J.C. (2025). Hodgkin Lymphoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/hodgkins.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf)
- [8] Horwitz, S.M., Ansell, S., . . . Zhang, Y.(2025). Primary Cutaneous Lymphomas Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/primary\\_cutaneous.pdf](https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf)
- [9] Horwitz, S.M., Ansell, S., . . . Zain, J. (2024). T-Cell Lymphomas Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/t-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf)
- [10] Kumar, S.K., Callander, N.S., . . . Vogl, D. (2024). Multiple Myeloma Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)
- [11] Kumar, S.K., Callander, N.S., . . . Vogl, D. (2025). Systemic Light Chain Amyloidosis Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/amyloidosis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf)
- [12] Kumar, S.K., Callander, N.S., . . . Vogl, D. (2025). Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma Version 2.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/waldenstroms.pdf](https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf)
- [13] Pollyea, D.A., Altman, J. K., . . . Wang, E. (2025). Acute Myeloid Leukemia (Age  $\geq$ 18 years) Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/aml.pdf](https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf)
- [14] Shah, N.P., Bhatia, R., . . . Yang, D.T. (2025). Chronic Myeloid Leukemia Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cml.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf)
- [15] Shah, B., Mattison, R. J., . . . Webster, J. (2024). Acute Lymphoblastic Leukemia. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/all.pdf](https://www.nccn.org/professionals/physician_gls/pdf/all.pdf)
- [16] Wierda, W.G., Brown, J., . . . Woyach, J.A. (2025). Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Version 3.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cll.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf)
- [17] Wierda, W.G., Brown, J., . . . Woyach, J.A. (2024). Hairy Cell Leukemia Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/hairy\\_cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf)
- [18] Zelenetz, A.D., Gordon, L.I., . . . Vose, J.M. (2025). B-Cell Lymphomas Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: May 2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf)

## 2025 Brachytherapy Breast Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Breast Cancer

### Ductal Carcinoma in Situ (DCIS) and Invasive Breast Cancer Guideline

Brachytherapy for ductal carcinoma in situ (DCIS) and invasive breast cancer is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. **ANY** of the following:
  - A. **10 fractions or less** for **ANY** of the following:
    - I. Definitive therapy to the tumor bed **ONLY**
    - II. Accelerated partial breast irradiation (APBI) for age 40 years or older **AND** Breast Cancer Gene (BRCA) negative for **ANY** of the following:
      1. Ductal Carcinoma In Situ (DCIS), screening detected of 3 cm or less and **ALL** of the following:
        - a. Low/intermediate nuclear grade
        - b. Negative margins size greater than or equal to 2 mm for DCIS
      2. Invasive ductal carcinoma and **ALL** of the following:
        - a. Estrogen receptor (ER) positive
        - b. Negative margins size greater than or equal to 2 mm
        - c. **NO** lymphovascular invasion (LVI), negative nodes
        - d. pT1 disease, grade 1-2
  - B. **1 fraction** for intraoperative radiation therapy (IORT)
- II. Physical ability and clinical status of **ANY** of the following:
  1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  2. Karnofsky performance status (KPS) grade of 70 or more<sup>1</sup>

**References:** [4] [1] [2] [3] [5] [6]



**LCD 37779**

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

<sup>1</sup>The Lansky performance status scale can be utilized for ages 16 or less.

## Brachytherapy Breast Cancer Summary of Changes

Brachytherapy Breast Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Ductal Carcinoma in Situ (DCIS) and Invasive Breast Cancer Guideline Changes:
  - Added grade 1-2 to pT1 disease
  - Added negative nodes indication to LVI criteria
  - Added new indication **1 fraction** for IORT due to it is designed to reduce radiation exposure to just those areas at most risk for recurrence and it maximally limits treatment to the normal surrounding tissue
  - APBI age criteria changed from 50 years or older to 40 years or older
  - Screening for DCIS changed from 2.5 cm or less to 3 cm or less
- Added definition for IORT.
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Breast Cancer References

- [1] Gradishar, W.J., Moran, M.S., . . . Young, J.S. (2025). Breast Cancer Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)
- [2] Stmad, V & Yashar, C. (2021). Breast brachytherapy. *Brachytherapy*, 20(5), 976-983.
- [3] Loibl, S., Andre, F., . . . Harbeck, N. (2024). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 35(2), 159-182.
- [4] Shah, C., Vicini, F.,...Wazer, D. (2018). The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. *Brachytherapy*, 17(1), 154-170.
- [5] Shaitelman, S. F., Anderson, B.M., . . . Lyons, J. A. (2023). Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*, 114, 112-132.
- [6] The American Society of Breast Surgeons Research Committee. (2018). Accelerated Partial Breast Irradiation. *The American Society of Breast Surgeons*. Retrieved: April 2025. <https://www.breastsurgeons.org/docs/statements/Consensus-Statement-for-Accelerated-Partial-Breast-Irradiation.pdf>

## 2025 Brachytherapy Central Nervous System Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

### Brachytherapy for Central Nervous System Cancer

#### **Glioma • Intracranial and Spinal Ependymoma • Medulloblastoma • Extensive Brain Metastases • Glioblastoma • Leptomeningeal Metastases • Limited Brain Metastases • Meningiomas • Metastatic Spine Tumors • Primary Central Nervous System Lymphoma • Primary Spinal Cord Tumors**

### **Guideline**

Brachytherapy for glioma, intracranial and spinal ependymoma, medulloblastoma, extensive brain metastases, glioblastoma, leptomeningeal metastases, limited brain metastases, meningiomas, metastatic spine tumors, primary central nervous system lymphoma and primary spinal cord tumors:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [1] [2] [3]



#### **LCD 37779**

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Central Nervous System Summary of Changes

Brachytherapy Central Nervous System guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Citations updated, evidence review completed.

## Brachytherapy Central Nervous System Cancer References

- [1] Halasz, L. M., Attia, A., . . . Shih, H. A. (2022). Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*, 12(5), 370-386.

- [2] Nabors, L.B., Portnow, J., . . . Willmarth, N.E. (2025). Central Nervous System Cancers Version 5.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf)
- [3] Vogelbaum, M. A., Brown, P. D., . . . Schiff, D. (2021). Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. *Journal of Clinical Oncology*, 40(5), 492-516.

## 2025 Brachytherapy Gastrointestinal Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Gastrointestinal Cancer

### Appendiceal Adenocarcinoma • Colon Cancer • Gastric Cancer • Rectal Cancer Guideline

Brachytherapy for the treatment of appendiceal adenocarcinoma, colon, gastric, or rectal cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [3] [4] [5] [6] [7] [12] [10]

### Anal Cancer Guideline

Brachytherapy for the treatment of anal cancer is considered medically appropriate if the documentation demonstrates **BOTH** of the following:

1. **3 fractions or less** for boost of residual tumor
2. Physical ability and clinical status of **ANY** of the following:
  - a. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - b. Karnofsky performance status (KPS) grade of 70 or more<sup>2</sup>

**References:** [4][1] [8]

---

<sup>2</sup>The Lansky performance status scale can be utilized for ages 16 or less.

## Esophageal Cancer Guideline

Brachytherapy for the treatment of esophageal cancer is considered medically appropriate if the documentation demonstrates **BOTH** of the following:

1. **3 fractions or less** for palliative treatment
2. Physical ability and clinical status of **ANY** of the following:
  - a. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - b. Karnofsky performance status (KPS) grade of 70 or more<sup>3</sup>

**References:** [2] [9]



### LCD 37779

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels

<sup>3</sup>The Lansky performance status scale can be utilized for ages 16 or less.

CODE	DESCRIPTION
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Gastrointestinal Cancer Summary of Changes

Brachytherapy Gastrointestinal Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Anal cancer guideline:
  - Added new criteria **3 fractions or less** for boost of residual tumor per published clinical data it is given as a radiation boost along with external radiation when a tumor isn't responding to regular chemoradiation (chemo plus external radiation).
- Esophageal Cancer:
  - Added new indication for palliative treatment as this can be a valuable particularly for relieving dysphagia (difficulty swallowing)
- Added definition for appendiceal carcinonoma
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Gastrointestinal Cancer References

- [1] Ali, Z. S., Solomon, E., . . . Taggar, A. S.(2022). High dose rate brachytherapy in the management of anal cancer: A review. *Radiotherapy and Oncology*, 171, 43-52.
- [2] Ajani, J.A., D'Amico, T.A., . . . Yoon, H. (2025). Esophageal or Esophagogastric Junction Cancers Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf)
- [3] Ajani, J.A., D'Amico, T.A., . . . Yoon, H. (2025). Gastric Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf)
- [4] Benson, A.B., Venook, A.P., . . . Wu, C. (2025). Anal Carcinoma Version Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal/pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal/pdf)

- [5] Benson, A.B., Venook, A.P., . . . Wu, C. (2025). Colon Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf)
- [6] Benson, A.B., Venook, A.P., . . . Wu, C. (2025). Rectal Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf)
- [7] Benson, A.B., Venook, A.P., . . . Wu, C. (2025). Small Bowel Adenocarcinoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/small\\_bowel.pdf](https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf)
- [8] Bourdais, R., Achkar, S., . . . Chagari, C. (2021). Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients' health quality perception. *National Library of Medicine*. Retrieved: April 2025. <https://pubmed.ncbi.nlm.nih.gov/27720203/>
- [9] Cisek, P., Strak, A., . . . Grzybowska-Szatkowska, L.(2024) . The Role of Brachytherapy Alone and in Combined Treatment of Esophageal Cancer—A Review. *MDPI* Retrieved: April 2025. <https://www.mdpi.com/2076-3417/14/7/2840>
- [10] Strnad, V.(2021). Gastrointestinal Brachytherapy. *Brachytherapy*, 22(1), 9-11.
- [11] Tempero, M.A., Malafa, M.P., . . . Wolpin, B.M. (2025). Pancreatic Adenocarcinoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf)
- [12] von Mehren, M., Kane, J.M., . . . Zimel, M. (2024). Gastrointestinal Stromal Tumors Version 1.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/gist.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf)

## 2025 Brachytherapy Genitourinary Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Genitourinary Cancer

### Bladder Cancer • Kidney Cancer • Post-Prostatectomy • Prostate Cancer, Very Low to Low Risk • Testicular Cancer Guideline

Brachytherapy for bladder cancer, kidney cancer, post-prostatectomy prostate cancer, very low to low risk prostate cancer, and testicular cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [6] [8] [12] [14]

### Prostate Cancer, Favorable Intermediate Risk

Brachytherapy for prostate cancer, favorable intermediate risk is considered medically appropriate if the documentation demonstrates **BOTH** of the following:

1. **2 fractions or less** for high dose rate (HDR) treatment
2. Physical ability and clinical status of **ANY** of the following:
  - a. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - b. Karnofsky performance status (KPS) grade of 70 or more<sup>4</sup>

**References:** [14] [13] [1]

### Penile Cancer Guideline

Brachytherapy for penile cancer is considered medically appropriate when the medical record demonstrates **ANY** of the following:

- I. Tumor 4 cm or more:
  1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.
- II. **ALL** of the following:
  - A. **2 fractions or less** for **ANY** of the following:
    1. Post circumcision and **ALL** of the following:

---

<sup>4</sup>The Lansky performance status scale can be utilized for ages 16 or less.

- a. T1-2, N0 disease
- b. Tumor size less than 4 cm
2. Post penectomy and primary site margin is positive
- B. Physical ability and clinical status of **ANY** of the following:
  - I. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - II. Karnofsky performance status (KPS) grade of 70 or more<sup>5</sup>

**References:** [7] [15] [3] [2]

## **Prostate Cancer, High and Very High Risk (Gleason Score of 8 to 10 OR PSA greater than 20) Guideline**

Brachytherapy for prostate cancer, high and very high risk (Gleason score of 8 to 10 **OR** PSA greater than 20) is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. **ANY** of the following:
  1. **1 fraction** using low dose-rate (LDR) **ONLY** as a boost
  2. **2 fractions or less** using HDR brachytherapy
- II. Physical ability and clinical status of **ANY** of the following:
  1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  2. Karnofsky performance status (KPS) grade of 70 or more<sup>6</sup>

**References:** [5] [9] [11] [4] [14] [10]

## **Prostate Cancer, Unfavorable Intermediate Risk (Gleason Score of 7 OR PSA 10-20) Guideline**

Brachytherapy for prostate cancer, unfavorable intermediate risk (Gleason score of 7 **OR** PSA 10-20) is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. **1 fraction**
- II. Life expectancy of 6 months or more

---

<sup>5</sup>The Lansky performance status scale can be utilized for ages 16 or less.

<sup>6</sup>The Lansky performance status scale can be utilized for ages 16 or less.

III. Physical ability and clinical status of **ANY** of the following:

1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
2. Karnofsky performance status (KPS) grade of 70 or more<sup>7</sup>

**References:** [5] [9] [11] [4] [14]



**LCD 37779**

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed

<sup>7</sup>The Lansky performance status scale can be utilized for ages 16 or less.

CODE	DESCRIPTION
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Genitourinary Cancer Summary of Changes

Brachytherapy for Genitourinary Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Prostate Cancer, Favorable Intermediate Risk:
  - Added new indication for high dose rate brachytherapy
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Genitourinary Cancer References

- [1] Hudson, J. M., Loblaw, A., . . . Morton, G. (2024). Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy: A 9-year update. *Radiology & Oncology*, 198110381
- [2] Mayer, C., Gasalberti, D. P., . . . Kumar, A. (2023) . Brachytherapy. *StatPearls*, . Retrieved: April 2025. <https://pubmed.ncbi.nlm.nih.gov/32965861/>
- [3] Crook, J.M., Haie-Meder, C., . . . Rivard, D=M.J. (2013). The American Brachytherapy Society Groupe Europeen de Curietherapie\_European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. *Brachytherapy*, 12(1), 191-198.
- [4] Eastham, J A., Aufferberg, G. B., . . . Boorjian, S. A. (2022). Clinically Localized Prostate Cancer: AUA/ASTRO Guideline 2022. *Journal of Urology*, 208(1), 10-33.
- [5] Fischer-Valuck, B. W., Gay, H. A., . . . Michalski, J. M. (2019). A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate. *Frontiers in Oncology*, 9, 1378.
- [6] Flaig, T.W., Spiess, P.E., . . . Wright, J.L. (2025). Bladder Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/bladder.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf)
- [7] Flaig, T.W., Spiess, P.E., . . . Wright, J.L. (2025). Penile Cancer Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/penile.pdf](https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf)

- [8] Gilligan, T., Lin, D.W., . . . Zhumkhawala, A. (2025). Testicular Cancer Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/testicular.pdf](https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf)
- [9] Henry, A., Pieters, B. R., . . . Hoskin, P. (2022). GEC-ESTRO ACROP prostate brachytherapy guidelines. *Radiotherapy and Oncology*, 167, 244-251.
- [10] Hudson, J., Loblaw, A., . . . Morton G. (2024). Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update *Radiotherapy and Oncology*, 198, Article 110381.
- [11] McLaughlin, P. W., Narayana, V. (2020). Progress in Low Dose Rate Brachytherapy for Prostate Cancer. *Seminars in Radiation Oncology*, 30(1), 39-48.
- [12] Motzer, R.J., Jonasch, E., . . . Zibelman, M. (2025). Kidney Cancer Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf)
- [13] Sanmamed, N., Joseph, L., . . . Helou, J.(2023). Long-term oncologic outcomes of low doserate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer. Zelefsky, M. (Eds.). *Brachytherapy* , Volume 22, Issue 2, March–April 2023, Pages 188-194. Philadelphia, PA: Elsevier.
- [14] Schaeffer, E.M., Srinivas, S., . . . Wong, J.K. (2024). Prostate Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)
- [15] Van Poppel, H., Watkin, N.A., . . . Kataja, V. (2013). Penile Carcinoma: ESMO Clinical Practice Guidelines. *Annals of Oncology*, 24(Suppl 6),V115-V124.

## 2025 Brachytherapy Gynecological Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Gynecological Cancer

### Cervical Cancer Guideline

Brachytherapy for cervical cancer is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. **3 fractions or less** and **ANY** of the following:

- A. Advanced disease, with or without sufficient regression, and brachytherapy is delivered using interstitial needles.
  - B. As a boost, post hysterectomy **AND** positive or close vaginal mucosal surgical margins
  - C. Cervix is intact and brachytherapy is delivered using ovoids, ring or cylinder (combined with the intrauterine tandem).
  - D. Definitive therapy for primary cervical cancer when surgery is not an option.
- II. Physical ability and clinical status of **ANY** of the following:
- 1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - 2. Karnofsky performance status (KPS) grade of 70 or more<sup>8</sup>

**References:** [6] [7] [1] [9]

## Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Guideline

Brachytherapy for ovarian cancer, fallopian tube cancer or primary peritoneal cancer:

- 1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [5]

## Uterine Neoplasms Guideline

Brachytherapy for uterine neoplasms is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. **ANY** of the following:
  - 1. **3 fractions or less** for boost with external beam radiotherapy (EBRT)
  - 2. **5 fractions or less** for postoperative high dose rate (HDR) vaginal brachytherapy alone
- II. Physical ability and clinical status of **ANY** of the following:
  - 1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - 2. Karnofsky performance status (KPS) grade of 70 or more<sup>9</sup>

<sup>8</sup>The Lansky performance status scale can be utilized for ages 16 or less.

<sup>9</sup>The Lansky performance status scale can be utilized for ages 16 or less.

**References:** [6] [8] [2]

## Vaginal Cancer Guideline

Brachytherapy for vaginal cancer is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. Clinical condition is **ANY** of the following:
  - A. **2 fractions or less** to gross nodes as a boost.
  - B. **10 fractions or less** for **ANY** of the following:
    1. Invasive cancer using HDR fractionation to the high-risk clinical target volume (HR-CTV).
    2. Very early stage cancer (less than 5 mm in size) and **ALL** of the following:
      - a. External beam radiation therapy is **NOT** needed.
      - b. HDR fractionation will be used.
      - c. Intracavitary approach
- II. Physical ability and clinical status of **ANY** of the following:
  1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  2. Karnofsky performance status (KPS) grade of 70 or more<sup>10</sup>

**References:** [3] [10]

## Vulvovaginal Melanoma Guideline

Brachytherapy for vulvovaginal melanoma is considered medically appropriate when the medical record demonstrates **ALL** of the following:

- I. Clinical condition is **ANY** of the following:
  - A. **8 fractions** for adjuvant therapy in primary disease only.
  - B. Unresectable gross disease treated with radiation therapy alone and **ANY** of the following:
    1. **5 fractions or less** as a boost external beam radiotherapy (EBRT)
    2. **10 fractions or less** with brachytherapy alone (small primaries or in situ disease)
- II. Physical ability and clinical status of **ANY** of the following:

---

<sup>10</sup>The Lansky performance status scale can be utilized for ages 16 or less.

1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
2. Karnofsky performance status (KPS) grade of 70 or more<sup>11</sup>

**Reference:** [4]



**LCD 37779**

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed

<sup>11</sup>The Lansky performance status scale can be utilized for ages 16 or less.

CODE	DESCRIPTION
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Gynecological Cancer Summary of Changes

Brachytherapy Gynecological Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Uterine neoplasm change:
  - Separated postoperative HDR and changed to **5 fractions or less**
- Vaginal Cancer change:
  - **5 fractions or less** changed to **10 fractions or less**
- Vulvovaginal Melanoma changes:
  - **5 fractions or less** for adjuvant therapy changed to **8 fractions or less**
  - **8 fractions or less** for boost changed to **5 fractions or less**
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively

## Brachytherapy Gynecological Cancer References

- [1] Abu-Rustum, N.R., Campos, S. M., . . . Wyse, E. (2025). Cervical Cancer Version 4.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf)
- [2] Abu-Rustum, N.R., Campos, S. M., . . . Wyse, E. (2025). Uterine Neoplasms Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf)
- [3] Abu-Rustum, N.R., Yashar, C.M., . . . Wyse, E. (2025). Vaginal Cancer Version 5.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/vaginal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/vaginal.pdf)
- [4] Abu-Rustum, N.R., Yashar, C.M., . . . Wyse, E. (2025). Vulvar Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/vulvar.pdf](https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf)
- [5] Armstrong, D.K., Alvarez, R.D., . . . Zsiros, E. (2025). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf)
- [6] Chargari, C., Deutsch, E., . . . Haie-Meder, C. (2019). Brachytherapy: An Overview for Clinicians. *CA: A Cancer Journal for Clinicians*, 69(5), 386-401.

- [7] Chino, J., Annunziata, C.M., . . . Viswanathan, A.N. (2020). Article title. *Radiation Therapy for Cervical Cancer: An ASTRO Clinical Practice Guideline, 10(4)*, 220-234.
- [8] Harkenrider, M. M., Abu-Rustum, N., . . . Erickson, B. A. (2023). Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline. *Practical Radiation Oncology, 13*, 41-65.
- [9] Chuk, E., Yu, C., . . . Han, K. (2019). Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer. *Radiation Oncology\*Biography\*Physics, 120(4)*, p1042-1051.
- [10] Reshko, L.B., Gaskins, J.T., . . . Silva, S.R.(2021). The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. *Brachytherapy, 20(1)*, 75-84.

## 2025 Brachytherapy Head and Neck Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Head and Neck Cancer

### Ethmoid Sinus Tumors • Maxillary Sinus Tumors • Mucosal Melanoma • Oral Cavity Cancer Guideline

Brachytherapy for ethmoid sinus tumors, maxillary sinus tumors, mucosal melanoma and oral cavity cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [7] [9] [8] [5]

### Hypopharynx Cancer • Laryngeal Cancer • Nasopharynx Cancer • Oropharynx Cancer Guideline

Brachytherapy for hypopharynx cancer, laryngeal cancer, nasopharynx cancer and oropharynx cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [7] [5]

## Thyroid Carcinoma Guideline

Brachytherapy for thyroid carcinoma:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [6]

## Uveal Melanoma Guideline

Brachytherapy for uveal melanoma is considered appropriate when the medical record demonstrates **ALL** of the following:

- I. **1 fraction**
- II. Definitive therapy for primary tumor
- III. Plaque brachytherapy is being used for **EITHER** of the following:
  - A. Upfront therapy after initial diagnosis
  - B. Post local recurrence following a prior local therapy
- IV. Tumor size is 2 cm or less in diameter.
- V. Physical ability and clinical status of **ANY** of the following:
  1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  2. Karnofsky performance status (KPS) grade of 70 or more<sup>12</sup>

**References:** [4] [3] [10] [11] [1]



### LCD 37779

See also, **LCD 37779**: Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

<sup>12</sup>The Lansky performance status scale can be utilized for ages 16 or less.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Head and Neck Cancer Summary of Changes

Brachytherapy Head and Neck Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Head and Neck Cancer References

- [1] (2014). The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. *American Brachytherapy Society*. Retrieved: May 2024. <https://www.americanbrachytherapy.org/consensus-statements/eye/>

- [2] Budrukkar, A., Guinot, L., . . . Kovacs, G. (2023). Function Preservation in Head and Neck Cancers. *Clinical Oncology*, 35(8), 497-506.
- [3] Chevli, N., Schefler, A. C., . . . Teh, B. S. (2021). taged Eye-Plaque Brachytherapy: A Novel Approach for Large Uveal Melanoma. *Advances in Radiation Oncology*, 6(4), 100712.
- [4] Chevli, N., Zuhour, R. J., . . . Teh, B. S. (2022). Contemporary trends in management of uveal melanoma. *Journal of Contemporary Brachytherapy*, 14(2), 123-129.
- [5] Guinot, J. L., Bacorro, W., . . . Tagliaferri, L. (2024). GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR. *Radiotherapy and Oncology*, 201, Article 110533.
- [6] Haddad, R.I., Bischoff, L., . . . Yeh, M.W. (2025). Thyroid Carcinoma Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf)
- [7] Pfister, D.G., Spencer, S., . . . Zhen, W. (2025). Head and Neck Cancers Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)
- [8] Merfeld, E. C., Witek, M. E., . . . Harari, P. M. (2023) .Interstitial Brachytherapy for Lip Cancer: Technical Aspects to Individualize Treatment Approach and Optimize Outcomes. *Pubmed* . Retrieved: April 2025. <https://pubmed.ncbi.nlm.nih.gov/36709044/>
- [9] Tucek, L., Sirak, I., . . . Petera, J. (2023) . High-dose-rate brachytherapy at 3 Gy per fraction for lip carcinoma: Treatment outcomes and toxicity at 5-years. *Pubmed* . Retrieved: April 2025. <https://pubmed.ncbi.nlm.nih.gov/37015847/#:~:text=These%20data%20support%20the%20use%20of%20HDR%20DBT,daily%20seems%20to%20be%20effective%20and%20safe.>
- [10] Swetter, S.M., Johnson, D., . . . Xing, Y. (2025). Melanoma: Uveal Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/uveal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)
- [11] Wong, A. J., Teh, B. S., . . . Schefler, A. C. (2022). Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques. *Journal of Contemporary Brachytherapy*, 14(2), 130-139.

## 2025 Brachytherapy Hepatobiliary Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Hepatobiliary Cancer

### Ampullary Adenocarcinoma Guideline

Brachytherapy for ampullary adenocarcinoma:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [7]

### Biliary Tract (Gallbladder • Intrahepatic Cholangiocarcinoma • Extrahepatic Cholangiocarcinoma) Cancer Guideline

Brachytherapy for biliary tract (gallbladder, intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma) cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [5] [2] [4]

### Hepatocellular Carcinoma Guideline

Brachytherapy for hepatocellular carcinoma (HCC) is considered medically appropriate if the the medical records demonstrate **BOTH** of the following:

1. **1 fraction** using CT-guided high dose rate (HDR) brachytherapy for **ANY** of the following:
  - a. Intrahepatic HCC recurrence following hepatic resection
  - b. Unresectable tumor
  - c. **Not** amenable to radiofrequency ablation
2. Physical ability and clinical status of **ANY** of the following:
  - a. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - b. Karnofsky performance status (KPS) grade of 70 or more<sup>13</sup>

**References:** [3] [1]

### Pancreatic Adenocarcinoma Guideline

Brachytherapy for the treatment of pancreatic adenocarcinoma:

---

<sup>13</sup>The Lansky performance status scale can be utilized for ages 16 or less.

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [11]



**LCD 37779**

See also, **LCD 37779:** Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Hepatobiliary Cancer Summary of Changes

Brachytherapy Hepatobiliary guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Hepatocellular Carcinoma Guideline changes:
  - Added new indications:
    - CT-guided high dose rate (HDR) brachytherapy
    - Intrahepatic HCC recurrence following hepatic resection
    - Unresectable tumor
    - **Not** amenable to radiofrequency ablation
- Added definitions:
  - High-dose-rate remote brachytherapy
  - Intrahepatic
  - Radiofrequency ablation
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Hepatobiliary Cancer References

- [1] Auer, T. A., Anhamm, M., . . . Colletini, F. (2024) . Effectiveness and safety of computed tomography-guided high-dose-rate brachytherapy in treating recurrent hepatocellular carcinoma not amenable to repeated resection or radiofrequency ablation. *European Journal of Surgical Oncology*, , Volume 50, Issue 7, Article 108429. Retrieved: April 2025. <https://www.clinicalkey.com/#!/content/1-s2.0-S0748798324004815?scrollTo=%23h10000428>
- [2] Benson, A.B., D'Angelica, M.I., . . . Yopp, A. (2025). Biliary Tract Cancers Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/btc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf)
- [3] Benson, A.B., D'Angelica, M.I., . . . Zhao, K. (2025). Hepatocellular Carcinoma Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/hcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf)
- [4] Gravely, A. K., Vibert, E., Sapisochin, G. (2022). Surgical treatment of intrahepatic cholangiocarcinoma. *Journal of Hepatology*, 77(3), 865-867.
- [5] Kodali, S., Shetty, A., . . . Ghobrial, R. (2021). Management of Intrahepatic Cholangiocarcinoma. *Journal of Clinical Medicine*, 10(11), 1-15.

- [6] Palta, M., Godfrey, D., . . . Koong, A.C. (2019). Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*, 9(5), 322-332.
- [7] Tempero, M.A., Malafa, M.P., . . . Wolpin, B.M. (2025). Ampullary Adenocarcinoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ampullary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ampullary.pdf)
- [8] Tempero, M.A., Malafa, M.P., . . . Wolpin, B.M. (2025). Pancreatic Adenocarcinoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf)

## 2025 Brachytherapy Pediatric Cancers

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 07/31/2025

Previous Review Date: New

Guideline Initiated: New

## Brachytherapy for Pediatric Cancers

### Pediatric Cancers Guideline

Brachytherapy for pediatric (less than or equal to 18 years of age) cancers:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [1] [3] [4] [5] [6] [7] [2]

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex

CODE	DESCRIPTION
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Pediatric Cancers Summary of Changes

Pediatric Cancer guideline is a new guideline:

- Brachytherapy is not a preferred modality due to tumors in pediatric patients are often located near critical organs, increasing the risk of radiation-induced damage.

## Brachytherapy for Pediatric Cancer References

- [1] Barth, M., Xavier, A.C., . . . Weinstein, J. (2025). Pediatric Aggressive Mature B-Cell Lymphomas 2.2025. *National Comprehensive Cancer Network*. Retrieved: July 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_b-cell.pdf)
- [2] Fajardo, R.D., Scarzello, G., . . . Mandeville, H.C. (2024). Brachytherapy for rhabdomyosarcoma: Survey of international clinical practice and development of guidelines. *Radiation Oncology Journal*, June 2024(Volume 195),110273.
- [3] Gajjar, A., Mahajan, A., . . . Zaky, W. (2025). Pediatric Central Nervous System Cancers 2.2025. *National Comprehensive Cancer Network*. Retrieved: July 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_cns.pdf)
- [4] Hua, C., Mascia, A.E., . . . Ulin, K.(2021). Advances in radiotherapy technology for pediatric cancer patients and roles of medical physicists: COG and SIOP Europe perspectives. *National Library of Medicine*. Retrieved: July 2025. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8030241/>

- [5] Inaba, H., Teachey, D., . . . Yanik, G. (2025). Pediatric Acute Lymphoblastic Leukemia Version 3.2025 *National Comprehensive Cancer Network*. Retrieved: July 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_all.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf)
- [6] Kelly, K., Hiniker, S.M., . . . Young, K.(2025). Pediatric Hodgkin Lymphoma 2.2025. *National Comprehensive Cancer Network*. Retrieved: July 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/ped\\_hodgkin.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ped_hodgkin.pdf)
- [7] Liu, K.X., Haas-Kogan, D.A., . . . Elhalawani, H. (2025). Radiotherapy for Primary Pediatric Central Nervous System Malignancies: Current Treatment Paradigms and Future Directions. *National Library of Medicine*. Retrieved: July 2025. <https://pubmed.ncbi.nlm.nih.gov/37703864/>

## 2025 Brachytherapy Sarcoma

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Sarcoma

### Desmoid Tumors Guideline

Brachytherapy for desmoid tumors:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [7]

### Kaposi Sarcoma Guideline

Brachytherapy for Kaposi sarcoma:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [2]

### Retroperitoneal/Intra-Abdominal Sarcoma Guideline

Brachytherapy for retroperitoneal/intra-abdominal sarcoma:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**Reference:** [7]

## Soft Tissue Sarcoma of Extremity, Body Wall or Head and Neck Guideline

Brachytherapy for soft tissue sarcoma of extremity, body wall or head and neck is considered medically appropriate when the medical record demonstrates **BOTH** of the following:

- I. **ANY** of the following:
  - A. **10 fractions or less** for adjuvant therapy with low dose-rate or high dose-rate brachytherapy for **ANY** of the following:
    - I. Administered with external beam radiation therapy (EBRT) for positive margins
    - II. Negative margins
  - B. IORT boost in neoadjuvant therapy for positive margins for **ANY** of the following:
    - I. **6 fractions or less** for microscopically positive disease
    - II. **7 fractions or less** for gross disease
- II. Physical ability and clinical status of **ANY** of the following:
  1. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  2. Karnofsky performance status (KPS) grade of 70 or more<sup>14</sup>

**References:** [7] [4] [3] [5] [6]



### LCD 37779

See also, **LCD 37779**: Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

<sup>14</sup>The Lansky performance status scale can be utilized for ages 16 or less.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Sarcoma Summary of Changes

Brachytherapy Sarcoma guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Soft Tissue Sarcoma of Extremity, Body Wall or Head and Neck Guideline:
  - Rephrased boost in neoadjuvant therapy for positive margins and added new indications:
    - **6 fractions or less** for microscopically positive disease
    - **7 fractions of less** for gross disease
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

- Citations updated, evidence review completed.

## Brachytherapy Sarcoma References

- [1] Naghavi, A.,O., Fernandez, N., . . . Harrison, L.B. (2017). The American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. *Brachytherapy*, 16(3), 466-489.
- [2] Reid, E., Suneja, G., . . . Wang, C. J. (2025 ). Kaposi Sarcoma Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/kaposi.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf)
- [3] Salermo, K. E. (2022). Radiation Therapy for Soft Tissue Sarcoma. *The Surgical Clinics of North America*, 102(4), Pages 567-582
- [4] Campbell, S. R., Shah, C., . . . Harrison, L. B.(2021). American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. *Brachytherapy*, 20(6), Pages 1200-1218.
- [5] Laskar, S., Manjali, J. J., . . . Chard, J. (2023). Brachytherapy for Organ and Function Preservation in Soft-Tissue Sarcomas in Adult and Paediatric Patients. *Clinical Oncology*, 35(8), 533-540.
- [6] Thakur, P., Aggarwal, V., . . . Parihar, N. (2024).In-depth feasibility study on conservative surgery, perioperative high-dose-rate brachytherapy, and external beam radiation therapy, with a focus on interstitial brachytherapy for soft tissue sarcomas: Insights from a single-institute experience. *Journal of Contemporary Brachytherapy*, 16(5), 362-370.
- [7] von Mehren, M., Kane, J.M., . . . Zimel, M. (2025). Soft Tissue Sarcoma Version 5.2024. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf)

## 2025 Brachytherapy Skin Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Skin Cancer

### Basal Cell Skin Cancer Guideline

Brachytherapy for basal cell skin cancer is considered medically appropriate if the medical record demonstrates **BOTH** of the following:

1. **9 fractions or less** for surface skin high dose rate for basal cell carcinoma
2. Physical ability and clinical status of **ANY** of the following:
  - a. Eastern cooperative oncology group (ECOG) performance status grade of 2 or less
  - b. Karnofsky performance status (KPS) grade of 70 or more<sup>15</sup>

**References:** [2] [1] [3] [6]

## Dermatofibrosarcoma Protuberans, Melanoma and Merkel Cell Carcinoma Guideline

Brachytherapy for dermatofibrosarcoma protuberans, melanoma and merkel cell carcinoma:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [4] [7]

## Squamous Cell Skin Cancer Guideline

Brachytherapy for squamous cell skin cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [2] [5]



### LCD 37779

See also, **LCD 37779**: Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session

<sup>15</sup>The Lansky performance status scale can be utilized for ages 16 or less.

CODE	DESCRIPTION
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Skin Cancer Summary of Changes

Brachytherapy Skin Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Basal Cell Skin Cancer Guideline changes:
  - Added indications:
    - **9 fractions or less** for surface skin high dose rate for basal cell carcinoma based on published clinical data, high dose rate brachytherapy decreases the number of clinical and dermoscopic features typical for basal cell carcinoma
- Added definition:
  - High dose rate brachytherapy
- Citations updated, evidence review completed.
- Updated ECOG/KPS scoring from 1 to 2 and 80 to 70 respectively.

## Brachytherapy Skin Cancer References

- [1] Bordeaux, J., Aasi, S. Z., . . . Yusuf, M. (2025). Basal Cell Skin Cancer Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/nmsc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf)
- [2] Likhacheva, A., Awan, M., . . . Devlin, P.M. (2020). Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. *Practical Radiation Oncology*, 10(1), 8-20.
- [3] Bordeaux, J., Blitzblau, R., . . . Yusuf, M.(2024). Dermatofibrosarcoma Protuberans Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/dfsp.pdf](https://www.nccn.org/professionals/physician_gls/pdf/dfsp.pdf)
- [4] Bordeaux, J., Blitzblau, R., . . . Yusuf, M. (2025). Merkel Cell Carcinoma Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/mcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf)
- [5] Bordeaux, J., Aasi, S. Z., . . . Yusuf, M. (2025). Squamous Cell Skin Cancer 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/squamous.pdf](https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf)
- [6] Krzysztofiak, T., Kamińska-Winciorek, G., . . . Wojcieszek, P. (2021) . Basal Cell Carcinoma Treated with High Dose Rate (HDR) Brachytherapy—Early Evaluation of Clinical and Dermoscopic Patterns during Irradiation. *MDPI* Retrieved: April 2025. <https://www.mdpi.com/2072-6694/13/20/5188>
- [7] Swetter, S.M., Johnson, D., . . . Xing, Y. (2025). Melanoma: Cutaneous Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf)

## 2025 Brachytherapy Thoracic Cancer

### Radiation Therapy

Copyright © 2025 WNS (Holdings) Ltd.

**Last Review Date:** 05/23/2025

Previous Review Date: 07/01/2024

Guideline Initiated: 06/30/2019

## Brachytherapy for Thoracic Cancer

### Mesothelioma, Non-Small Cell Lung Cancer Stage I-III, Small Cell Lung Cancer Limited and Extensive Stage and Thymoma/Thymic Cancer Guideline

Brachytherapy for mesothelioma; non-small cell lung cancer, stage I-III; small cell lung cancer, limited and extensive stage and thymoma/thymic cancer:

1. The role of this therapy is uncertain/unclear in the current evidence. Requests for this therapy require review by a physician reviewer, medical director and/or the individual's healthplan.

**References:** [1] [2] [3] [4]



**LCD 37779**

See also, **LCD 37779**: Intraoperative Radiation Therapy at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

## Brachytherapy Procedure Codes

**Table 1. Brachytherapy Associated Procedure Codes**

CODE	DESCRIPTION
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77767	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel
77768	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels

CODE	DESCRIPTION
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels
77778	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate

## Brachytherapy Thoracic Cancer Summary of Changes

Brachytherapy Thoracic Cancer guideline from 2024 to 2025 had the following changes per the NCCN/ASTRO:

- Citations updated, evidence review completed.

## Brachytherapy Thoracic Cancer References

- [1] Riely, G. J., Wood, D.E., . . . Yau, E. (2025). Non-Small Cell Cancer Version 3.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)
- [2] Riely, G. J., Wood, D.E., . . . Yau, E. (2024). Thymomas and Thymic Carcinomas Version 1.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/thymic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf)
- [3] Ganti, A.K.P., Loo, Jr., B.W., . . . Waqar, S.N. (2025). Small Cell Lung Cancer Version 4.2025. *National Comprehensive Cancer Network*. Retrieved: March 2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf)
- [4] Riely, G. J., Wood, D.E., . . . Yau, E. (2025). Mesothelioma: Pleural Version 2.2025. *National Comprehensive Cancer Network*. Retrieved: April 2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/meso\\_pleural.pdf](https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf)

## Brachytherapy definition section

**Accelerated partial breast irradiation (APBI)** is a type of radiation therapy given only to the part of the breast that has cancer in it. Accelerated partial-breast irradiation gives a higher dose over a shorter time than is given in standard whole-breast radiation therapy and may be given using internal or external sources of radiation. Also called partial-breast irradiation.

**Acute lymphoblastic leukemia (ALL)** is a type of cancer of the blood and bone marrow where blood cells are made. The disease progresses rapidly and creates immature blood cells. The word "lymphocytic" in ALL refers to the white blood cells called lymphocytes. It is the most common type of cancer in children, and treatments result in a good chance for a cure. ALL can also occur in adults, though the chance of a cure is greatly reduced.

**Acute myeloid leukemia (AML)** is a malignant neoplasm characterized by the overproduction of immature myeloid precursor cells (blasts) in the bone marrow and peripheral blood, leading to anemia, thrombocytopenia and neutropenia and is diagnosed by the presence of more than 20% myeloid blasts in the peripheral blood or bone marrow.

**Adenocarcinoma** is a malignant tumor originating in glandular epithelium.

**Adjuvant** treatment refers to enhancing the effectiveness of medical treatment.

**Ampullary adenocarcinoma** are tumors originating from the ampulla of Vater (formed by 3 anatomical components: the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct).

**Anal cancer** is a disease in which malignant (cancer) cells form in the tissues of the anus

**Appendiceal carcinoma**, also known as appendix cancer, is a rare form of cancer that originates in the appendix.

**Basal cell carcinoma (BCC)** is a skin cancer derived from and preserving the form of the basal cells of the skin.

**B-cell lymphoma** is a type of cancer that forms in B-cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are many different types of B-cell non-Hodgkin lymphomas. These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

**Biliary tract** involves the organs and ducts that make and store bile (a fluid made by the liver that helps digest fat), and release it into the small intestine. The biliary tract includes the gallbladder and bile ducts inside and outside the liver.

**Bladder cancer** is cancer that forms in tissues of the bladder (the organ that stores urine).

**Boost** refers to an additional dose of radiation to a very small component or part of the initial targeted field or body part that is being treated for a tumor.

**Brachytherapy** is a form of radiation therapy, which utilizes a radioactive source placed in or in close proximity to the tumor. It can be done by placing the radioactive source on the surface of the body or within a body cavity depending on the area to be treated. Temporary brachytherapy places a delivery device, such as a catheter, needle, or applicator into the tumor. Medical imaging helps position the radiation sources. The doctor may insert the delivery device into a body cavity such as the vagina or uterus (intracavitary). Or, the doctor may insert an applicator (needle or catheter) into body tissues (interstitial). High dose-rate (HDR) treatments deliver radiation over

10 to 20 minutes per session. Low dose-rate (LDR) treatments deliver radiation over 20 to 50 hours. Pulsed dose-rate (PDR) treatments deliver radiation in periodic pulses.

**BRCA gene** (BRCA1 and BRCA2) are genes that normally help repair damaged DNA and prevent cancer development. Mutations in these genes can significantly increase the risk of breast, ovarian, prostate, and other cancers. Having a BRCA mutation doesn't guarantee cancer development, but it does mean a higher risk, especially for breast and ovarian cancers.

**Breast cancer** is a disease in which cells in the breast grow out of control. The kind of breast cancer depends on which cells in the breast turn into cancer. There are different kinds of breast cancer, including invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ (DCIS), paget's disease, medullary, mucinous, and inflammatory breast cancer.

**Buccal mucosa** consists of the inner lining of the cheeks.

**Cervical cancer** forms in tissues of the cervix (the organ connecting the uterus and vagina).

**Chronic lymphocytic leukemia (CLL)** is the most common type of leukemia in adults. It's a type of cancer that starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then moves into the blood.

**Chronic myeloid leukemia (CML)**, also known as chronic myelogenous leukemia, is a type of cancer that starts in certain blood-forming cells of the bone marrow.

**Colon cancer** is a type of cancer that begins in the large intestine (colon).

**Definitive treatment** is the treatment plan for a disease or disorder that has been chosen as the best one for a patient after all other choices have been considered.

**Dermatofibrosarcoma protuberans (DFSP)** is a rare type of skin cancer that starts in connective tissue cells in the middle layer of the skin (dermis).

**Desmoid tumor** is a soft tissue tumor that forms in fibrous (connective) tissue, usually in the arms, legs or abdomen. It may also occur in the head and neck. Desmoid tumors are usually benign (not cancer). They often recur (come back) after treatment and spread to nearby tissue, but they rarely spread to other parts of the body.

**Ductal carcinoma in situ (DCIS)** is any of a histologically variable group of precancerous growths or early carcinomas of the lactiferous ducts that have the potential of becoming invasive and spreading to other tissues.

**Eastern Cooperative Oncology Group (ECOG) scale** describes an individual's level of functioning in terms of the ability to care for one's self, daily activity and physical ability (eg, walking, working).

**Table 1. ECOG Performance Status Scale**

<b>Grade</b>	<b>ECOG PERFORMANCE STATUS</b>
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

Grade	ECOG PERFORMANCE STATUS
2	Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
3	Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
4	Completely disabled; cannot carry on any selfcare; totally confined to bed or chair
5	Dead

Source: <https://ecog-acrin.org/resources/ecog-performance-status/>

**Ependymoma** is a type of brain tumor that begins in the cells lining the spinal cord central canal (fluid-filled space down the center) or the ventricles (fluid-filled spaces of the brain). Ependymomas may also form in the choroid plexus (tissue in the ventricles that makes cerebrospinal fluid).

**Esophageal cancer** is cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach).

**Extensive stage** describes cancers that have spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, or to other parts of the body (including the bone marrow).

**Fallopian tube cancer** is cancer that develops in the fallopian tubes rather than the ovaries.

**Gastric cancer** also called stomach cancer, is cancer that forms in tissues lining the stomach.

**Glioblastoma** is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma usually occurs in adults and affects the brain more often than the spinal cord.

**Glioma** is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function.

The **hard palate** is the bony, front part of the roof of the mouth.

**Hairy cell leukemia** is a chronic leukemia that is usually of B-cell origin and is characterized by malignant cells with a ciliated appearance.

**Hepatocellular** is relating to or involving liver cells.

**High-dose-rate remote brachytherapy definition** is a type of internal radiation treatment in which the radioactive source is removed between treatments. Also called high-dose-rate remote radiation therapy and remote brachytherapy.

**Histiocytic neoplasm** is a group of rare disorders in which too many histiocytes (a type of white blood cell) build up in certain tissues and organs, including the skin, bones, spleen, liver, lungs, and lymph nodes.

**Hodgkin lymphoma** is a malignant lymphoma marked by the presence of Reed-Sternberg cells and characterized by progressive enlargement of lymph nodes, spleen and liver and progressive anemia.

**Hypopharyngeal** refers to the bottom part of the throat.

**Intra-abdominal** means being within or going into the abdomen

**Intracavitary radiation therapy** is a type of internal radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into a body cavity such as the chest cavity or the vagina.

**Intrahepatic** is something that is situated or occurring within or originating in the liver.

**Intraoperative Radiation Therapy (IORT)** is an intensive radiation treatment that is administered during surgery, and allows direct radiation to the target area while sparing normal surrounding tissue.

**Intermediate-grade DCIS (Grade 2):** Cells exhibit more variability in size and shape, and a higher rate of mitosis, indicating faster growth than low-grade DCIS.

**Invasive breast cancer** means that the cancer cells have grown through the lining of the ducts into the surrounding breast tissue

**Kaposi sarcoma** is a cancer that arises from cells lining blood and lymph vessels, typically presenting as purple, brown, or red lesions on the skin or in the mouth.

**Karnofsky performance status (KPS)** is an assessment tool for functional impairment. It can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. In most serious illnesses, the lower the Karnofsky score, the worse the likelihood of survival.

**Table 2. KARNOFSKY PERFORMANCE STATUS SCALE**

Score	Status
100	Normal, no complaints; no evidence of disease
90	Able to carry on normal activity; minor signs or symptoms of disease
80	Normal activity with effort, some signs or symptoms of disease
70	Cares for self but unable to carry on normal activity or to do active work
60	Requires occasional assistance but is able to care for most of personal needs
50	Requires considerable assistance and frequent medical care
40	Disabled; requires special care and assistance
30	Severely disabled; hospitalization is indicated although death not imminent
20	Very ill; hospitalization and active supportive care necessary
10	Moribund
0	Dead

Source: <https://ecog-acrin.org/resources/ecog-performance-status/>

**Kidney cancer** is cancer that forms in tissues of the kidneys.

**Laryngeal cancer** is cancer that forms in tissues of the larynx (area of the throat that contains the vocal cords and is used for breathing, swallowing, and talking).

**Limited stage** means the cancer is only on one side of the chest and can be treated with a single radiation field.

**Local therapy for cancer** is treatment that is directed to a specific organ or limited area of the body, such as the breast or an abnormal growth on the skin. Examples of local therapy used in

cancer are surgery, radiation therapy, cryotherapy, laser therapy, and topical therapy (medicine in a lotion or cream that is applied to the skin).

**Low grade** refers to cancer cells that look more like normal cells and tend to grow and spread more slowly than high-grade cancer cells.

**Lumpectomy** a surgical operation in which a lump is removed from the breast, typically when cancer is present but has not spread

**Lymphoid neoplasm** is a neoplasm composed of a lymphocytic cell population which is usually malignant (clonal) by molecular genetic and/or immunophenotypic analysis. Lymphocytic neoplasms include Hodgkin and non-Hodgkin lymphomas, acute and chronic lymphocytic leukemias, and plasma cell neoplasms.

**Lymphoplasmacytic lymphoma**, also called Waldenström macroglobulinemia, is indolent (slow-growing) type of non-Hodgkin lymphoma marked by abnormal levels of IgM antibodies in the blood and an enlarged liver, spleen, or lymph nodes.

**Lymphovascular invasion (LVI)** indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist.

**Medulloblastoma** is fast-growing type of cancer that forms in the cerebellum (the lower, back part of the brain). Medulloblastomas tend to spread through the cerebrospinal fluid to the spinal cord or to other parts of the brain. They may also spread to other parts of the body, but this is rare. Medulloblastomas are most common in children and young adults. They are a type of central nervous system embryonal tumor.

**Melanoma** is a highly malignant tumor that starts in melanocytes of normal skin or moles and metastasizes rapidly and widely.

**Meningioma** is a tumor, usually benign, arising from meningeal tissue of the brain

**Merkel cell carcinoma** is a very rare disease in which malignant (cancer) cells form in the skin.

**Mesothelioma** is a usually malignant tumor derived from mesothelial tissue (such as the tissue that lines the peritoneum or pleura).

**Metastases** is the spread of a disease-producing agency (such as cancer cells) from the initial or primary site of disease to another part of the body.

**Mucosal melanoma** is a melanoma that starts in the moist membranes that line the inside of the body, including the digestive tract. It is a rare but aggressive disease and is usually diagnosed in advanced stages.

**Multiple myeloma** is a blood cancer that develops in plasma cells in the bone marrow. Plasma cells are white blood cells that produce antibodies to protect the body from infection. In multiple myeloma, the plasma cells grow too much, crowding out normal bone marrow cells.

**Myelodysplastic syndrome (MDS)** is a type of cancer in which the bone marrow does not make enough healthy blood cells (white blood cells, red blood cells, and platelets) and there are abnormal cells in the blood and/or bone marrow. When there are fewer healthy blood cells, infection, anemia, or bleeding may occur.

**Myeloid/Lymphoid Neoplasms with Eosinophilia** is a stem cell leukemia/lymphoma with rearrangements involving chromosome 8p11 (FGFR1). These are aggressive, rare, pluripotent stem cell disorder with poor prognosis.

**Myeloproliferative neoplasm** is a group of diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets.

**Nasopharyngeal** refers to the nose and pharynx (the hollow tube inside the neck that starts behind the nose and ends at the top of the trachea and esophagus).

**Neoadjuvant treatment** is treatment (such as chemotherapy or hormone therapy) administered before primary cancer treatment (such as surgery) to enhance the outcome of primary treatment.

**Non-small cell lung cancer** is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are adenocarcinoma (most common), squamous cell carcinoma and large cell carcinoma. Non-small cell lung cancer is the most common of the two main types of lung cancer (non-small cell lung cancer and small cell lung cancer).

**Oral cavity** refers to the mouth. It includes the lips, the lining inside the cheeks and lips, the front two thirds of the tongue, the upper and lower gums, the floor of the mouth under the tongue, the bony roof of the mouth, and the small area behind the wisdom teeth.

**Oropharyngeal** refers to the part of the throat at the back of the mouth behind the oral cavity.

**Ovarian cancer** is cancer that forms in the tissues of the ovary (one of a pair of female reproductive glands in which the ova or eggs are formed).

**Palliative treatment** is treatment given to help relieve the symptoms and reduce the suffering caused by cancer or other life-threatening diseases. Palliative therapy may help a person feel more comfortable, but it does not treat or cure the disease.

**Pancreatic cancer** is cancer that forms in the cells of the pancreas

**Penile cancer** is a rare cancer that forms in the penis (an external male reproductive organ). Most penile cancers are squamous cell carcinomas (cancer that begins in flat cells lining the penis).

**Perineural invasion (PNI)** refers to the invasion of cancer to the space surrounding a nerve. It is common in head and neck cancer, prostate cancer and colorectal cancer.

**Plaque radiotherapy (brachytherapy)** is a type of radiation therapy used to treat eye tumors. A thin piece of metal (usually gold) with radioactive seeds placed on one side is sewn onto the outside wall of the eye with the seeds aimed at the tumor. It is removed at the end of treatment, which usually lasts for several days.

**Positive margin** means that cancer cells are found at the edge of the tissue that was removed during surgery. This indicates that not all cancer cells may have been successfully removed from the patient's body.

**Primary bone cancer** is cancer that forms in cells of the bone. Some types of primary bone cancer are chondrosarcoma, Ewing sarcoma, malignant fibrous histiocytoma, and osteosarcoma.

**Primary central nervous system lymphoma** is a disease in which malignant (cancer) cells form in the lymph tissue of the brain and/or spinal cord.

**Primary cutaneous lymphoma** are a heterogenous group of lymphoproliferative neoplasms, lymphatic proliferation is limited to the skin with no involvement of lymph nodes, bone marrow or viscera

**Primary peritoneal cancer** is cancer that forms in the peritoneum and has not spread there from another part of the body.

**Primary spinal cord tumor** is a tumor that originates in the spine. They are relatively rare, typically benign (noncancerous) and represent a small percentage of spinal tumors. Malignant tumors may also originate in the spine, although more often they spread to the spine from elsewhere in the body.

**Prostate** is a gland in the male reproductive system. The prostate surrounds the part of the urethra (the tube that empties the bladder) just below the bladder, and produces a fluid that forms part of the semen.

**Prostatectomy** is a surgery to remove part or all of the prostate and some of the tissue around it, including the seminal vesicles.

**Prostate-specific antigen (PSA)** is a protein made by the prostate gland and found in the blood. Prostate-specific antigen blood levels may be higher than normal in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate gland.

**Radiofrequency ablation (RFA)** is a minimally invasive medical procedure that uses heat generated by radio waves to destroy abnormal tissue. It's commonly used to treat pain, certain cancers, and heart rhythm disorders by selectively targeting and ablating, or destroying, the targeted tissue.

**Rectal cancer** is cancer that begins in the rectum

**Recurrent disease** is characterized by repeated alternations between acute relapse and long remission. Cancer that has recurred (come back), usually after a period of time during which the cancer could not be detected. The cancer may come back to the same place as the original (primary) tumor or to another place in the body. Also called recurrence.

**Retroperitoneal** means situated or occurring behind the peritoneum.

**Salvage therapy** is treatment that is given after the cancer has not responded to other treatments.

**Sarcomas** are rare cancers that develop in the bones and soft tissues including fat, muscles, blood vessels, nerves, deep skin tissues and fibrous tissues.

**Small cell lung cancer** is a highly malignant form of cancer that affects the lungs, tends to metastasize to other parts of the body, is characterized by small round or oval cells which resemble oat grains and have little cytoplasm.

**Small lymphocytic lymphoma** is a slow growing non-Hodgkin lymphoma that affects B cells (also known as B lymphocytes), which are specialized white blood cells that produce immunoglobulins (also called antibodies) that help protect against infection and disease.

**Squamous cell carcinoma (SCC)** is carcinoma that is made up of or arises from squamous cells (stratified epithelium that consists at least in its outer layers of small scale like cells) and usually occurs in areas of the body exposed to strong sunlight over many years.

**Systemic light chain amyloidosis** is a protein misfolding and metabolism disorder in which insoluble fibrils are deposited in various tissues, causing organ dysfunction and eventually death.

**Systemic mastocytosis** is a rare disease in which too many mast cells (a type of immune system cell) are found in the skin, bones, joints, lymph nodes, liver, spleen, and gastrointestinal tract.

**T-Cell lymphoma** is a type of cancer that forms in T-cells (a type of immune system cell). T-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most T-cell lymphomas are non-Hodgkin lymphomas. There are many different types of T-cell non-Hodgkin lymphomas. These include mycosis fungoides, anaplastic large cell lymphoma and precursor T-cell lymphoblastic lymphoma.

**Thymoma and thymic carcinoma** are diseases in which malignant (cancer) cells form on the outside surface of the thymus.

**Thyroid carcinoma** is a cancer that forms in the thyroid gland (an organ at the base of the throat that makes hormones that help control heart rate, blood pressure, body temperature, and weight).

**Uterine neoplasm** is a malignant tumor that starts in the cells of the uterus.

**Uveal melanoma** begins in the cells that make the dark-colored pigment, called melanin, in the uvea or uveal tract of the eye. Uveal melanoma of the iris is usually a small tumor that grows slowly and rarely spreads to other parts of the body. Uveal melanoma of the ciliary body and choroid are usually larger tumors and are more likely to spread to other parts of the body.

**Vaginal cancer** is cancer that forms in the tissues of the vagina (birth canal).

**Vulvar cancer** is cancer of the vulva (the external female genital organs, including the clitoris, vaginal lips and the opening to the vagina).

**Waldenstrom macroglobulinemia** is a rare, slow-growing type of non-Hodgkin lymphoma. It's a blood cell cancer that starts in malignant B-cells.

## Disclaimer section

### Purpose

The purpose of the HealthHelp's clinical guidelines is to assist healthcare professionals in selecting the medical service that may be appropriate and supported by evidence to safely improve outcomes. Medical information is constantly evolving, and HealthHelp reserves the right to review and update these clinical guidelines periodically. HealthHelp reserves the right to include in these guidelines the clinical indications as appropriate for the organization's program objectives. Therefore the guidelines are not a list of all the clinical indications for a stated procedure, and

associated Procedure Code Tables may not represent all codes available for that state procedure or that are managed by a specific client-organization.

## Clinician Review

These clinical guidelines neither preempt clinical judgment of trained professionals nor advise anyone on how to practice medicine. Healthcare professionals using these clinical guidelines are responsible for all clinical decisions based on their assessment. All Clinical Reviewers are instructed to apply clinical indications based on individual patient assessment and documentation, within the scope of their clinical license.

## Payment

The use of these clinical guidelines does not provide authorization, certification, explanation of benefits, or guarantee of payment; nor do the guidelines substitute for, or constitute, medical advice. Federal and State law, as well as member benefit contract language (including definitions and specific contract provisions/exclusions) take precedence over clinical guidelines and must be considered first when determining eligibility for coverage. All final determinations on coverage and payment are the responsibility of the health plan. Nothing contained within this document can be interpreted to mean otherwise.

## Registered Trademarks (®/™) and Copyright (©)

All trademarks, product names, logos, and brand names are the property of their respective owners and are used for purposes of information and/or illustration only. Current Procedural Terminology (CPT)<sup>®</sup>™ is a registered trademark of the American Medical Association (AMA). No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from HealthHelp.

## National and Local Coverage Determination (NCD and LCD)



### NOTICE

To ensure appropriate review occurs to the most current NCD and/or LCD, always defer to <https://www.cms.gov/medicare-coverage-database/search.aspx>.

## Background

National Coverage Determinations (NCD) and Local Coverage Determinations (LCD) are payment policy documents outlined by the Centers for Medicare and Medicaid Services (CMS) and



A WNS COMPANY

the government's delegated Medicare Audit Contractors (MACs) that operate regionally in jurisdictions.

CMS introduced variation between different jurisdictions/Medicare Audit Contractors (MACs) and their associated covered code lists with the transition to ICD 10. The variation resulted in jurisdictions independently defining how codes are applied for exclusions, limitations, groupings, ranges, etc. for the medical necessity indications outlined in the NCD and LCD. Due to this variation, there is an inconsistent use/application of codes and coverage determinations across the United States between the different MACs.

In addition, **WITHOUT** notice, CMS can change the codes that indicate medical necessity and the format of the coverage determinations/associated documents (eg, Articles). This is an additional challenge for organizations to keep up with ongoing, unplanned changes in covered codes and medical necessity indications.

## Medical Necessity Codes

Due to the variation in code application between jurisdictions/MACs and that updates can happen without notification, HealthHelp is not able to guarantee full accuracy of the codes listed for any Coverage Determination, and advises that prior to use, the associated Coverage Determination Articles are reviewed to ensure applicability to HealthHelp's programs and any associated NCDs and LCDs.

### For Internal Use Only:

11248 11249 11253 11282 11325 11328 11333 11349 11350 11351 11352 11354 11355 11356  
11358 11359 11360 11361 11362 11365 11366 11367 11368 11369 11370 11374 11375 11394  
11395 11396 11565